DEVELOPMENTAL CHEMOTHERAPY

$188,635P01FY2002CANIH

Sloan-Kettering Institute For Cancer Res, New York NY

Investigators

Linked publications & trials

Paper 26101208 Paper 23338004 Paper 22100494 Paper 21558399 Paper 20534736 Paper 18691169 Paper 18245545 Paper 17936848 Paper 17897298 Paper 17785570 Paper 17520176 Paper 17473203 Paper 17409804 Paper 17332293 Paper 17235042 Paper 17194908 Paper 17114630 Paper 17070363 Paper 17002808 Paper 16398649 Paper 16357841 Paper 16319952 Paper 16243819 Paper 16197608 Paper 16115124 Paper 16033840 Paper 15882729 Paper 15867253 Paper 15725085 Paper 15680748 Paper 15640822 Paper 15636684 Paper 15578708 Paper 15367410 Paper 15315964 Paper 15135836 Paper 15058795 Paper 14752077 Paper 14752067 Paper 14739217 Paper 14717777 Paper 14695223 Paper 14679001 Paper 14534876 Paper 13130314 Paper 12899717 Paper 12860944 Paper 12850191 Paper 12832588 Paper 12796370 Paper 12690304 Paper 12676776 Paper 12649134 Paper 12590414 Paper 12559285 Paper 12548573 Paper 12351594 Paper 12163360 Paper 12061743 Paper 12012302 Paper 11981011 Paper 11773181 Paper 11675334 Paper 11331333 Paper 11297240 Paper 11264154 Paper 11252010 Paper 11157476 Paper 11001890 Paper 10999734 Paper 10974080 Paper 10944130 Paper 10913810 Paper 10856101 Paper 10784634 Paper 10741705 Paper 10715285 Paper 10699601 Paper 10623917

Abstract

DESCRIPTION: (Applicant's Description) Chemotherapy remains one of the principal means of cancer treatment. Over the past 3 decades, this grant has allowed Memorial Hospital to rapidly test and apply new treatments to a variety of cancers. The overall goal of this project will be to conduct Phase I studies of new single agents and combination therapies developed at Memorial Hospital for application in disease specific Phase II and Phase III trials. Highest priority for new studies will be given to ideas and compounds developed within the Memorial Sloan Kettering Cancer Center for which we hold the IND. The clinical trials to be performed will include both molecular markers of response and pharmacokinetics when appropriate. All trials in this project are Phase I studies. The clinical trials performed in this project will be grouped into 3 specific aims. Specific aim 1 is the development of novel agents including geldanamycin analogs, 10 - propargyl-10 deazaaminopterin, arsenic trioxide, PS341, and desoxyepothilone B. Specific Aim Two is a target based therapy program utilizing Pyroxamide and is directed at the development of this putative differentiation agent. Finally, in Specific aim 3 correlative science is described to support these trials. Each of these clinical studies will be linked to pharmacokinetic and molecular laboratory correlative studies. Through this work, we expect to identify new, more active treatments for the successful management of human malignancies.

View original record on NIH RePORTER →